Background: Cancer of unknown primary (CUP) is diagnosed at a metastatic stage, conferring an unfavorable prognosis. The natural history of the disease is poorly understood, which complicates diagnosis, treatment and followup. Population-based survival data are lacking regarding location and histology of metastases. Results: Adenocarcinoma accounted for 70% of all extranodal cases with a 12-month survival of 17% and the median survival of 3 months. Adenocarcinoma was also the most common histology (33.4%) when metastases were limited to lymph nodes, with a 12-month survival of 41% and median survival of 8 months. For extranodal metastases, the extremes in survival were small intestinal cancer with poor prognosis and mediastinal cancer with favorable prognosis. For nodal metastases, patients affected in the head and neck, axillary and inguinal regions had the best prognosis and those with abdominal and intrapelvic metastases the worst prognosis.
introduction
Cancer of unknown primary site (CUP) accounts for ∼ 3% to 5% of all cancers but, because it is typically detected when disseminated, it ranks among the top six causes of cancer deaths in Western countries [1] [2] [3] . It can be called 'an orphan disease' because it is usually diagnosed based on metastases and the primary tumor remains undetected in many patients [3] [4] [5] . Autopsy data suggest that the lung, liver, pancreas and gastrointestinal tract are common sites for the primary tumors. The orphan disease designation is appropriate because, as a metastatic disease, CUP is often disregarded as an entity since only primary cancers are usually considered, and hardly anything is known about the etiology. A recent study demonstrated familial clustering of CUP and the association of CUP with many other cancers, especially tumors originating from organs suspected to be responsible for many CUP diagnoses [6] . Accordingly, CUP occurred often in relatives of patients with cancers of the lung, colorectum, liver, ovary and kidney, among others. Familial clustering of these cancers suggests a shared genetic basis, which could reveal joint mechanisms for metastasis. CUP might be a useful focus for studies aimed at identifying general mechanisms relevant in the context of metastasis [5] .
Treatment of CUP is guided by the suspected origin of the primary tumor and an extensive diagnostic work-up is therefore applied in order to identify the tissue of origin [7] [8] [9] [10] . Prognosis was shown to be better when a likely primary tumor was identified and the appropriate treatment was applied accordingly [11] . Depending on the patient series, some 10%-40% of CUP patients are diagnosed with metastasis in lymph nodes, while the remaining patients present with metastasis in their internal organs [1, 12, 13] . Even though the primary tumor often evades identification, some clinicopathologic features of CUP identify groups of patients with a prognostic advantage [14] [15] [16] [17] . In particular, the prognosis is favorable in CUP limited to lymph nodes and with histology other than adenocarcinoma. In contrast, liver metastasis and the involvement of multiple sites including the brain, the lung/pleura and bone signal an unfavorable prognosis [1, 3, 12, 13, 18, 19] . The favorable prognosis in patients with lymph node metastases is probably due to the fact that no vital function is immediately threatened. Nonetheless, survival does vary according to which lymph nodes are affected [1, 12, 13, 20] . However, comprehensive prognostic data on CUP are sparse and most recent studies have focused on the outcomes of clinical trials on defined CUP subgroups [21] .
In the present study, we address patient characteristics and survival in CUP patients according to site-and histologyspecific involvement of lymph nodes and internal organs. Diagnostic data from 1987 to 2008 on all Swedish CUP patients were obtained from the Swedish Cancer Registry. This is by far the largest study conducted on the subject. To obtain reliable survival data, population-based studies are preferred because they include all patients. In contrast, hospital-based studies may be influenced by biases due to selected patient populations.
patients and methods
The study population was retrieved from the latest update of the FamilyCancer Database of year 2008, which is a subset of the national MigMed2 dataset at the Center for Primary Health Care Research (Lund University, Malmö, Sweden). The database was created by linking the Multigeneration Register of Statistics Sweden with the Swedish Cancer Registry of The National Board of Health and Welfare. It has been used in recent studies on CUP [6, 22] . National Census Data and the Swedish population register of Statistics Sweden were incorporated into the dataset to obtain information on the socioeconomic status of study subjects. All linkages were carried out using the national 10-digit civic identification number that is assigned to each person in Sweden for his or her lifetime. This number was replaced by a serial number to provide anonymity.
The Swedish Cancer Registry is based on a compulsory notification of cases. The completeness of cancer registration was estimated to be over 95% since the 1970s. Tumors were identified according to the ninth revision of International Classification of Diseases (ICD-9) between 1987 and 1992 [23] . Any subsequent codes were translated back to ICD-9 in order to help with the follow-up of incidence trends. ICD-9 codes were used in the present study because these codes define the location of metastasis according to primary affected organ sites [24] . The code numbers for extranodal CUP were 197 through 199. During the period of the study, 90%-95% of CUP cases were histologically verified. More than 12.1 million individuals comprise the Family-Cancer Database.
Each person was followed from diagnosis of cancer to death, date of emigration or censored at 31 December 2008, whichever came first. The relative risk of death in any cancer death was estimated as hazard ratio (HR) using Cox regression (PROC PHREG, SAS Version 9.2; SAS Institute, Cary, NC). The data were adjusted for age (continuous variable), sex and period (1987-1997 and 1998-2008) . CUP without specification of site, defined by code 199 (CUP 199), was used as reference in each analysis. We believe that code 199 was commonly used for CUP affecting multiple sites at diagnosis. The basis of this assumption is the fact that the causes of death in these patients covered practically all common cancers, starting with liver and lung cancer as the most common ones. Survival curves were derived by Kaplan-Meier method (PROC LIFETEST, SAS Version 9.2; SAS Institute).
The study was approved by the Ethics Committee at Lund University.
results
nodal involvement only Table 1 shows patient numbers and diagnostic ages of CUP patients diagnosed with metastasis to the lymph nodes (code 196, N = 1903); the data are also shown for CUP of unspecified location (code 199, N = 7730). Lymph node metastases of the head and neck region (N = 898) and of the axilla (N = 385) were the most common ones. For the former, there was a male predominance, perhaps because of the head-, neck-and lungassociated primary tumors, while the latter was more common in females, implicating breast as the initial disease. There was a large female predominance for metastasis in pelvic nodes, a rare site of probably ovarian origin. Overall, patients with nodal metastasis were diagnosed 5 years younger than CUP original articles Annals of Oncology 199 patients; there was a 10-year difference between diagnostic ages depending on the nodal location, multiple sites with the lowest age (60 years) and pelvic nodes with the highest age (71 years). Table 1 also shows data on the histological type of metastasis. For CUP 199, adenocarcinoma was the prominent histology (65.6%), while for nodal tumors, adenocarcinoma was only somewhat more common (33.4%) than undifferentiated (26.8%) and squamous cell carcinoma (23.6%); melanoma accounted for 16.1% of the nodal cases. Histologies varied according to the nodal location. Squamous cell carcinoma was the most common histology in head and neck nodes but in all other nodes, adenocarcinoma prevailed, followed by melanoma in axillary and inguinal nodes and by undifferentiated cancer in other nodes. Table 2 shows 12-month survival fractions, median survival times and HRs for cancer death after various lymph node involvements according to histology. CUP 199 of all histologies is used as a reference with a 24% survival at month 12, 3-month median survival and an HR of 1.00. Overall, lymph node involvement was compatible with a favorable prognosis of 53% survival at month 12, 14-month median survival and an HR 0.53. Among nodal tumors, adenocarcinoma was most fatal with an HR of 0.69 and squamous cell carcinoma was least fatal with an HR of 0.30. Lymph nodal metastases in the axilla were associated with the most favorable prognosis (HR = 0.40), followed by inguinal (HR = 0.45) and head and neck (HR = 0.51) nodal metastases. Intrapelvic (1.27) and intraabdominal (1.14) nodal involvement associated with the worst prognosis. At most sites with at least 100 patients, adenocarcinoma and undifferentiated cancer associated with the worst prognosis and squamous cell histology associated with the most favorable prognosis; the exceptions were axillary lymph nodes for which squamous cell histology associated with the worst prognosis. We carried out a gender-specific analyses but the only result with significant differences Kaplan-Meier survival graphs for cancer deaths are shown in Figure 1 by the affected lymph nodes. As a reference, survival in CUP 199 is also shown. In adenocarcinoma ( Figure 1A ), the survival was most favorable for patients with axillary nodal involvement, stabilizing to close to 40% in 10 years. Patients with inguinal metastasis survived also better than patients with other nodal involvements. Less than 10% of CUP 199 patients survive 2 years. For squamous cell carcinoma ( Figure 1B) , patient with head and neck and inguinal metastasis had an over 50% survival, higher than for patients with other affected lymph nodes. For melanoma ( Figure 1C ), the survival ranged between 30% and 40%, largely independent on the location of the metastasis (log-rank Pvalue = 0.04 of borderline significance); the rare abdominal and pelvic metastasis had exceptionally poor prognosis. For undifferentiated cancer ( Figure 1D ), patients with axillary and upper limb metastasis survived best, with ∼40% survival in 10 years, while for patients with other nodal metastasis the survival at 10 years was <30%. The survival patterns of adenocarcinoma ( Figure 1A ) and undifferentiated cancer ( Figure 1D ) were quite similar with the exception of a better survival for axillary involvement in adenocarcinoma and a better survival for head and neck involvement for undifferentiated cancer.
extranodal involvement
The total number of extranodal CUP patients was 17 008. Table 3 shows patient numbers and diagnostic ages of the patients with the site of metastasis defined (codes 197 and 198 , N = 9278) and not defined (code 199, N = 7730). The liver (N = 4209), pleura (N = 1039) and bone (N = 1001) were the most common organ sites of metastasis. More women were affected overall and among patients with skin and (retro)peritoneal metastases. Men had an excess of rare metastases in the mediastinum, kidney and 'other parts of nervous system'. The median diagnostic ages ranged from 64 years for patients with brain and spinal cord and ovarian tumors to 76 years for those with pleural and small intestinal tumors. Adenocarcinoma was 
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the most common histological type, accounting for 70% of all cases. Adenocarcinoma histology ranged from 91.6% in ovarian tumors to <50% in the mediastinum, other respiratory organs and skin (Table 1) . Squamous cell carcinoma was rare, reaching over 10% share only for the mediastinum and kidney. Melanomas were also rare, most cases being found in the skin and brain. Undifferentiated tumors accounted for ∼20% overall with the highest proportions in the mediastinum and other urinary organs, which were rare sites.
Kaplan-Meier survival graphs, showing 24 months of follow-up with regard to histology-specific cancer deaths are shown in Figure 2 . The survival curves for adenocarcinoma (9545 deaths) and undifferentiated cancer (2821 deaths) were almost superimposable, with a 12-month survival (shown by a vertical line) of 17% and 16%, respectively. Half of the observed deaths occurred within the first 3 months after diagnosis, i.e. the median survival time was 3 months. The 12-month survival for squamous cell carcinoma (557 deaths) was 36% and for melanoma (705 deaths) it was 51%; the median survival times were 6 and 13 months. For CUP overall, the 12-month survival was 19% and the median survival was 3 months.
Kaplan-Meier survival graphs for adenocarcinoma patients are shown in Figure 3A and B. Both 12-month survival rate and median survival can be found in Table 4 . The 12-month survival was lowest for patients with small intestinal (5%) and liver (7%) cancers. The 12-month survival for CUP 199 was 19%, and survival curves for cancer in the peritoneum (12-month survival 17%), other digestive organ and spleen (19%), lung (20%) and pleura (21%) were almost superimposable with CUP 199 and they were not shown. Bone adenocarcinoma showed also a 21% survival fraction, skin 27%, suprarenal gland and other sites 28% (not shown) and brain 32%. Patients with ovarian (36%), colorectal (40%) and mediastinal tumors (43%) had the most favorable survival. original articles
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For undifferentiated cancer, patients with liver metastasis showed the poorest 12-month survival of 7% ( Figure 4A, B) . Patients with CUP 199 and pleural, peritoneal, brain, skin and bone tumors had a survival between 15% and 20%; the lung and suprarenal and other sites had a survival fraction close to 30% and that for the mediastinum was 41%. In the figure, colorectal and small intestinal curves are not shown because of small numbers; the 12-month survival fractions were 14% and 0%.
The survival rates differed much for squamous cell carcinoma ( Figure 5A ) and melanoma ( Figure 5B), depending on the affected sites. For these histological types, the 12-month survival was 5% and 12% for patients with liver metastasis and it was 22% and 21% for patients with brain metastasis. Only 15% of patients with squamous cell carcinoma in the bone survived 12 months. The survival in CUP 199 was ∼50% for both histologies. The best survival of any recorded tumors was for small intestinal melanoma (75%); for the much more common skin melanoma it was also high (65%). Table 4 shows, in addition to 12-month survival fractions and median survival times, HRs for cancer death according to histology using CUP 199 of all histologies a reference with an HR of 1.00. The data were adjusted for age, sex and period. Overall, tumors in the liver (HR = 1.59), (retro)peritoneum (HR = 1.25) and other digestive organs and spleen (HR = 1.27) had the worst prognosis. In the liver, all histologies signaled poor prognosis, the worst being for squamous cell carcinoma (HR = 2.12) and melanoma (HR = 2.00). For the (retro) peritoneum, both adenocarcinoma and undifferentiated cancer conveyed a poor prognosis. An overall favorable prognosis was observed for the suprarenal and other organs (0.83, squamous cell 0.63 and melanoma 0.61), skin (0.64, melanoma 0.35) and mediastinum (0.76); also, colorectal adenocarcinoma showed a favorable prognosis (0.70).
discussion nodal data
The novel aspects of the present study were the nationwide coverage, definition of lymph node location at diagnosis for 1903 patients and complete follow-up, with 1212 cancer deaths. Typically, patients diagnosed with lymph node CUP (ICD9 codes 1960-1968) did not have detectable disease in other organs. The reference population was patients diagnosed with CUP 199 of unknown location. The limitations included lack of data on the number of affected lymph nodes (there was a code for multiple affected lymph nodes, but it was rarely used) and treatment. Although the study had nationwide coverage, relatively few patients had certain types of lymph node metastasis.
The data showed that the overall HR for patients with any lymph node metastasis was 0.53 (compared with patients with CUP 199). Survival at 12 months was 53%, compared with 24% for CUP 199 patients, and the median survival times were 14 and 3 months, respectively. The HRs ranged from 0.69 for adenocarcinoma to 0.61 for undifferentiated cancer, 0.40 for melanoma and 0.30 for squamous cell carcinoma. The location of the affected lymph nodes had a major effect on survival. Intrapelvic (1.27) and intra-abdominal (1.14) lymph node metastases were the most fatal and those in the axilla (0.40), inguinal region (0.45) and head and neck (0.51), the least fatal. The lowest HR for any site/histology type was for squamous cell carcinoma of the inguinal region (0.23). With regard to the histology, patients with adenocarcinoma and undifferentiated histologies had the worst prognoses. This applied even to lymph nodes associated with a more favorable prognosis. Clear exceptions were lymph nodes of the axilla, for which adenocarcinoma signaled a favorable prognosis, compatible with the primary being in the breast. One hypothesis for the poor prognosis of patients with intrapelvic and intraabdominal nodal involvement of possible ovarian origin relates to immunology. Regulatory T cells are strongly suppressive of immune reactions and are known to be present in high numbers in ovarian cancer [25] .
How do these findings relate to known prognostic data? Previous clinical data have established a favorable subset for the presenting CUP patients. Lymph node involvement only is considered a positive characteristic and has been described as 'adenocarcinoma involving only axillary lymph nodes' (our HR = 0.34), 'squamous cell carcinoma involving cervical lymph nodes' (our HR = 0.28) and 'isolated inguinal adenopathy of squamous cell histology' (our HR = 0.23) [3, 19] . Indeed, these clinical diagnostic markers showed the lowest HRs in our study. However, the established favorable subgroup did not include patients with any histology in the axillary lymph nodes, whose HR in the present study was 0.40, showing that, in addition to adenocarcinoma, melanoma and undifferentiated cancers in these lymph nodes can be associated with relatively good survival.
Unfavorable prognosis has not been associated with any subgroup of patients with only lymph node metastasis [3, 19] . Compared with CUP 199, metastases in intrapelvic and intra- 
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abdominal lymph nodes should be considered unfavorable prognostic signs, at least equal in severity to the diagnosis of CUP. They are rare manifestations, but the Kaplan-Meier curves showed that survival was poor, irrespective of histology. Thus, metastasis of any histology in intrapelvic and intraabdominal lymph nodes should be added to the list of unfavorable prognostic markers. The Kaplan-Meier survival curves showed striking differences between favorable and unfavorable metastatic involvement. To our knowledge, no such data have been shown before, with the exception of the comparison of survival in patients with supraclavicular and other nodal metastasis [12] . The present data show that the mortality for patients who survive the first few years tends to reach a plateau within 10 years, after which cancer-specific mortality stabilized. The level of the survival plateau ranged from 60% to some 20% for the favorable metastatic sites, depending on histology.
Much of the available CUP literature on lymph node metastasis has been nonspecific with regard to site, histology, age and sex. The present data fill these gaps. In the MD Anderson Cancer Center series of 1400 CUP patients, of whom 666 had lymph node metastasis, poorly differentiated cancers were the most common histological type (40%), while squamous cell carcinoma only accounted for 17% of lymph node histologies [16] . In addition, the distribution of affected lymph nodes differed between the MD Anderson study and the present study: 40% of the affected lymph nodes were in the thorax and mediastinum in the MD Anderson study compared with our 4.2%. MD Anderson is a referral center and this previous study was therefore not population based.
extranodal data
The strengths of the present study include nationwide coverage of 17 008 extranodal CUP patients, 9278 with a defined metastatic location and 7730 without a specified location. Additionally, the data covered 1987 through 2008 and are thus relatively recent. Previous studies with survival data based on affected organs have been limited to <1000 extranodal patients and have been hospital based [11, 13, 16] . The nationwide inclusion of cases is extremely important. The dramatic death rates for adenocarcinoma and undifferentiated cancer, the most common CUP subtypes, in the first months after diagnosis illustrate the fatality of the disease and serve as a reminder of the special requirements for any study aimed at assessing survival rates in this disease. Referral centers receive surviving patients, which for adenocarcinoma and undifferentiated cancer may account for only a small proportion of the initial patient population. This point is well illustrated by the available survival figures. For example, Greco and Pavlidis [21] cited nine studies on median survival times for CUP patients. For three cancer registry-based studies, survival ranged from 2.75 to 4 months; for hospital-based studies, it ranged from 3 to 11 months. Median survival in the present study was 3 months. The selected patient populations in hospital-based studies are probably the reason why even expert reviewers cite survival figures for CUP of ≥6 months and refer to histological distributions enriched in those subtypes commensurate with favorable survival. Frailty of patients is recognized in the prognostic evaluation of CUP because performance status is a favorable prognostic sign [15, 18] .
The novel data showed that the two most common histologies, adenocarcinoma and undifferentiated cancer, which respectively accounted for 70.0% and 20.7% of the present CUP cases, were associated with the poorest prognoses (12-month survival rates of 17% and 16%, respectively, and a median survival time of 3 months) and had almost superimposable survival curves. The similarity between the curves does not imply deviations in pathological evaluations but rather reflects the limited overall variation in patient survival between the two histologies and various metastatic sites. For example, the 12-month survival rates for adenocarcinoma and undifferentiated cancer were identical (7%) for liver cancer. The large majority of cancers of these two histological types showed a 12-month survival rate of close to 20%. For both histological types, small intestinal cancer showed the worst survival of all sites, while mediastinal cancers showed the best survival. The largest difference between the two histologies was for colorectal cancer, for which the 12-month survival rate in patients with adenocarcinoma was 40% compared with 14% for patients with undifferentiated cancer. Differences in survival rates between patients with adenocarcinoma and undifferentiated cancer were also noted for brain cancer (survival rates 32% and 15%, respectively) and skin cancer (27% and 13%, respectively).
Liver adenocarcinoma metastasis is a known unfavorable prognostic sign, as is multiple brain, lung and bone adenocarcinoma metastases [17] [18] [19] . The present study on 4209 patients showed that liver metastasis was an unfavorable prognostic sign, irrespective of histology, with median survival times ranging between 1 and 2 months. According to five hospital-based studies with a combined total of 711 patients, the median survival time was 5.9 months (range 1.7-10) [26] . In the present study, we had no data on number of metastases, but patients with brain, lung and bone adenocarcinomas showed somewhat better than average survival. According to a hospital-based study on 47 CUP patients with brain metastasis, the median survival was 4.8 months [27] . The present study on 645 patients with brain metastasis showed a somewhat longer median survival of 7 months. Patients with small intestinal adenocarcinoma and undifferentiated cancer had a dismal prognosis, even worse than those with liver cancers. Small intestinal adenocarcinoma and undifferentiated cancer should be added to the list of unfavorable prognostic indicators. The relatively favorable 12-month survival of patients with mediastinal cancers (over 40%) indicates that mediastinal cancer should be included in the list of prognostic indicators. Although we had no data on metastases at multiple sites, we believe that CUP 199, the largest subgroup in this study, often presented with multiple affected sites. The reason for this conclusion is the fact that the causes of death of these patients included cancers at diverse organ sites.
In previous survival studies, patients with squamous cell carcinoma have been shown to have a favorable prognosis compared with those with adenocarcinoma. In a cancer registry-based study on 76 subjects, the median survival times were 3.5 months for squamous cell carcinoma and 2.5 months for adenocarcinoma [15] . In two hospital-based studies, the original articles Annals of Oncology reported differences in survival between the histologies were 9 and 4 months in one and 22 and 9 months in the other [14, 16] . In the present study, the median survival time for patients with squamous cell carcinoma was 6 months. However, the present data showed that squamous cell metastasis in the liver was associated with a poor prognosis, with a 12-month survival rate of 5%. Bone metastasis was also associated with a poor prognosis (12-month survival rate 15%). A recent review of the global literature on CUP melanoma identified skin involvement in 222 patients, visceral tissue involvement in 211 patients and bone involvement in 31 patients; median survival in the visceral involvement group was given as 3-16 months [28] . The present study covered 98 cases of skin metastasis, 138 of visceral metastasis and 10 of bone metastasis, as well as 459 melanomas in unspecified sites. Median survival was 13 months. Survival was favorable in patients with skin melanoma (median time 34 months) but poor in those with liver (1 month) and brain (6 months) metastatic melanomas.
Our epidemiological results facilitate clinical decision making and encourage mechanistic studies into the biology of CUP. The latter might eventually translate into improved treatment options for CUP patients. 
